INTRODUCTION
============

Medulloblastoma is a malignant, invasive embryonal tumor in the cerebellum or fourth ventricle and accounts for 12--25% of all central nervous system tumors. Medulloblastoma is the most common malignancy affecting children with an annual incidence of five per 100,000 among children \<15 years of age [@b1-cln_72p294]. Although surgery remains the major treatment for medulloblastoma, there is still controversy regarding the impact of resection on the prognosis of patients with medulloblastoma. Furthermore, in cases of adherent medulloblastoma to the brainstem, complete resection is extremely difficult. In addition, metastasis via the cerebrospinal fluid is common; thus, medulloblastoma patients often have a poor prognosis and a high mortality rate [@b2-cln_72p294].

Clinically, the prognosis of patients with medulloblastoma is often determined according to the pathological type, which also provides a reference for the application of adjunctive therapies, such as radiotherapy and chemotherapy [@b3-cln_72p294],[@b4-cln_72p294]. Currently, the World Health Organization (WHO) classification system for medulloblastoma is based on histomorphology. However, patients with the same pathological type of medulloblastoma still have distinct genetic backgrounds. Therefore, the prognosis of patients with medulloblastoma may vary even within the same WHO pathological type [@b2-cln_72p294].

Recent studies on medulloblastoma have revealed that it is more accurate to stratify risk based on the molecular phenotype, which is also helpful to guide clinical treatment and determine clinical prognosis [@b5-cln_72p294],[@b6-cln_72p294]. Currently, medulloblastoma is divided into several subtypes according to the molecular phenotypes: WNT, Sonic hedgehog (SHH) and non-SHH/WNT [@b7-cln_72p294],[@b8-cln_72p294]. In addition, Ellison et al. [@b2-cln_72p294] differentiated medulloblastoma subtypes by immunohistochemistry, and the authors validated their findings using microarray analyses. Ellison et al. found that it is feasible to differentiate different subtypes of medulloblastoma by immunohistochemistry [@b2-cln_72p294]. In the present study, the molecular phenotyping methods for medulloblastoma reported by Ellison et al. [@b2-cln_72p294] were utilized to detect the expression of Yes associated protein 1 (YAP1) and GRB2-associated protein 1 (GAB1) by immunohistochemistry.

YAP1 is an auxiliary initiator of oncogene transcription and can promote cellular proliferation and transformation [@b9-cln_72p294]. Gene expression profiling of medulloblastoma reveals that it is highly expressed in the WNT and SHH subtypes of medulloblastoma and is not observed in the other two medulloblastoma subtypes [@b9-cln_72p294],[@b10-cln_72p294]. In contrast, GAB1 belongs to the Gab family and has specificity in the SHH signaling pathway of medulloblastoma cells [@b2-cln_72p294]. In the present study, YAP1 protein served as a specific marker of the WNT and SHH medulloblastoma subtypes while GAB1 was used as a specific marker of the SHH medulloblastoma subtype.

In this retrospective observational study, we evaluated the association of molecular subtypes, clinical characteristics and pathological types with the prognosis of patients with medulloblastoma. The primary outcome was overall survival (OS). Risk factors associated with survival, disease progression and recurrence were analyzed with a univariate Cox regression analysis, and the identified significant risk factors were further analyzed via Kaplan-Meier survival curves. YAP1 served as a specific marker of the WNT and SHH subtypes; GAB1 served as a specific marker of the SHH subtype. This analysis may provide information pertinent to treatment decisions for patients with medulloblastoma.

MATERIALS AND METHODS
=====================

Study design
------------

In this retrospective analysis, we reviewed the medical records of 40 children with pathologically proven medulloblastoma who underwent surgical resection at the Affiliated Children's Hospital of Fudan University between January 2004 and June 2014. Medulloblastoma was diagnosed and classified into the following subtypes according to the 2016 WHO classification system of central nervous system tumors [@b11-cln_72p294]: classic subtype, desmoplastic/nodular subtype, extensive nodularity subtype or large cell/anaplastic subtype.

Inclusion criteria included the following: absence of another severe disease diagnosis, a complete medical record with followed-up data, and medulloblastoma tissues that were fixed in 10% neutral formalin and embedded in paraffin following resection. All deaths were a result of disease progression or recurrence; however, one patient who died within 3 days after surgery was excluded. Two other patients were excluded due to a lack of follow-up data. This study was approved by the institutional review board of Fudan University.

Radiotherapy and chemotherapy protocols
---------------------------------------

After 28 days following the resection procedure, patients underwent postoperative craniospinal irradiation (CSI) delivering a median craniospinal dose of 36 Gy with additional boosts to the posterior fossa up to 54.0--55.8 Gy weekly for 8 weeks. Chemotherapy was initiated 6 weeks after radiotherapy in eight 6-week courses consisting of 4 weeks of chemotherapy followed by 2 weeks of rest. Specifically, patients received an intravenous infusion of cisplatin (75 mg/m^2^) on Day 0; intravenous bolus infusion of vincristine (1.5 mg/m^2^, max of 2 mg/dose) on Days 1, 7, and 14; and intravenous infusion of cyclophosphamide (1,000 mg/m^2^) on Days 21 and 22. Examinations of the patients' skulls and spines by MRI were performed once every 12 weeks.

Survival analysis
-----------------

The OS time was defined as the time interval between surgery and death or the last follow-up and was expressed in months. The disease progression-free survival (PFS) duration was defined as the time interval between date of surgery and date of progression-free, last follow-up, or death. The recurrence-free duration was calculated from the date of surgery to the date of recurrence, last follow-up, or death. Censored data were considered if the patient survived at the last follow-up and was marked in the survival curve.

Karnofsky performance scale
---------------------------

Postoperative Karnofsky performance scale (KPS) scores were determined for all patients during hospitalization. In this scale, a score of 100 indicates that the physical condition of the patient is normal without evidence of disease, while a score of 10 indicates rapid, fatal disease progression.

Immunohistochemistry
--------------------

Immunochemistry analysis of YAP1 and GAB1 expression was performed as previously described [@b2-cln_72p294]. After surgical resection, medulloblastoma tissues were fixed in 4% neutral formalin and embedded in paraffin. The paraffin-embedded tissues provided by the Department of Pathology in the Affiliated Children's Hospital of Fudan University were cut into 4-μm sections. After routine processing with xylene, graded ethanol solutions, and 3% H~2~O~2~ for 10 min, antigen retrieval was performed in 0.05 M citrate buffer (pH=6.0) at 100°C for 5--10 min followed by blocking in goat serum for 10 min. Immunohistochemistry analyses were performed using a EnVision two-step immunohistochemistry system (DAKO, Kyoto, Japan) with anti-GAB1 polyclonal antibodies (1:50, Abcam; Cambridge, MA, USA) and anti-YAP1 polyclonal antibodies (1:50, Abcam) for 1 h at 37°C. After washing, sections were incubated in HRP-conjugated goat anti-rabbit IgG (H+L; Jackson ImmunoResearch; West Grove, PA, USA) for 1 h at 37°C. Visualization was performed with DAB.

The immunohistochemistry results were semi-quantified. Five fields were randomly selected from each section at a magnification of 200×, and the positive cells were counted and averaged. Cells positive for YAP1 exhibited brown granules in the nucleus and cytoplasm; GAB1-positive cells exhibited granules in the nucleus. Positive cells were counted to obtain an average. Sections undergoing hematoxylin and eosin (HE) staining also served as controls. At a magnification of 400×, the proportion of positive cells ≥30% at the strong positive area was regarded as positive (+) while the proportion of positive cells \<30% was regarded as negative (-).

Statistical analysis
--------------------

All data were presented as frequencies and percentages and were assessed with a Chi-squared test. A Cox proportional hazard model was performed to identify effectors of poor survival outcome. To quantify the strength of the association between a potential risk factor and death, disease progression, or medulloblastoma recurrence, hazard ratios (HR) and 95% confidence intervals (CI) were estimated and reported. Given the limited sample size, only significant variables with *p*-values \<0.01 in the univariate analysis were used for further multivariable analyses. If both postoperative radiotherapy and postoperative chemotherapy met the criterion, the variable "both postoperative radiotherapy and chemotherapy" was used instead. In cases where no variable with *p*-values \<0.01 was identified in the univariate analysis, a multivariable analysis was not performed. A *p*-value \<0.05 was considered significant. All statistical analyses were two-sided and performed using IBM SPSS statistics for Windows version 22.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

Patient demographics
--------------------

Patient characteristics are summarized in [Table 1](#t1-cln_72p294){ref-type="table"}. Patients with partial or complete resection exhibited similarities in most characteristics except a higher percentage of patients with partial resection received radiotherapy after surgery than did patients with complete resection (100% *vs*. 50%, *p*=0.022). Among the 40 patients, most were males (n=29, 72.5%) and ≥3 years of age (n=29, 72.5%). Clinical features of central medulloblastoma (n=36, 90%), complete tumor resection (n=34, 85%) and classic subtype (n=33, 82.5%) were commonly observed among the patients. Other subtypes included the desmoplastic/nodular (D) subtype in 3% (n=1) and the large cell/anaplastic (LC/A) subtype in 15% (n=6). At least 80% of the patients presented with an M stage at M0 and T stage at T3 or above ([Table 1](#t1-cln_72p294){ref-type="table"}). Calcification (n=14) or pre-operative cerebral tonsillar herniation (n=9) was observed in 23%--35% of patients. Whereas 57.5% of patients (n=23) received radiotherapy, only 35% (n=14) were treated with chemotherapy after surgery. The postoperative KPS score was ≥80 in 80% of the patients (n=32), suggesting near to normal activity and either the absence of disease signs/symptoms or the presence of only mild disease signs/symptoms.

Molecular subtype analysis
--------------------------

The medulloblastoma subtypes were identified using YAP1 and GAB1 immunohistochemistry analyses. [Supplementary Figure S1](#f2-cln_72p294){ref-type="fig"} shows representative images of the WNT, SHH, and non-SHH/WNT subtypes. As shown in [Table 1](#t1-cln_72p294){ref-type="table"}, 20% of the tumors (n=8) were the WNT subtype, and 32.5% (n=13) were the SHH subtype. The remaining 47.5% of patients (n=19) presented with the non-SHH/WNT subtype of medulloblastoma.

Univariate and multivariable analyses of predictors of poor OS
--------------------------------------------------------------

As shown in [Table 1](#t1-cln_72p294){ref-type="table"}, 32.5% of the children survived to the last follow-up. The factors associated with the OS of medulloblastoma patients are shown in [Table 2](#t2-cln_72p294){ref-type="table"}. The univariate analysis indicated that patients with M1 stage (HR=3.63, 95% CI: 1.30--10.09, *p*=0.014) or calcification (HR=3.10, 95% CI: 1.28--7.53, *p*=0.012) were at significantly greater risk of death.

Treatment with radiotherapy, chemotherapy, or both following surgical resection positively impacted patient survival. The HRs were 0.34 (95% CI: 0.1--0.74, *p*=0.007) for radiotherapy, 0.19 (95% CI: 0.06--0.59, *p*=0.004) for chemotherapy, and 0.28 (95% CI: 0.10--0.79, *p*=0.017) for both therapies. A postoperative KPS score ≥80 was also associated with a lower risk of death (HR=0.31, 95% CI: 0.12--0.80, *p*=0.015). Relative to patients with non-SHH/WNT tumors, patients with the WNT (HR=0.16, 95% CI: 0.05--0.58, *p*=0.005) or SHH (HR= 0.29, 95% CI: 0.12--0.73, *p*=0.008) subtypes were less likely to have a poor outcome.

In the multivariable analysis, the effect of the SHH molecular subtype disappeared ([Table 2](#t2-cln_72p294){ref-type="table"}). Postoperative treatment with both radiotherapy and chemotherapy (HR=0.16, 95% CI: 0.04--0.66, *p*=0.011) and the WNT molecular subtype (HR=0.10, 95% CI: 0.02--0.43, *p*=0.002) continued to be associated with better survival outcomes ([Table 2](#t2-cln_72p294){ref-type="table"}).

Kaplan-Meier survival analysis
------------------------------

The Kaplan-Meier curves displaying factors associated with OS are shown in [Figure 1](#f1-cln_72p294){ref-type="fig"}. Four of five patients with M1 stage or above died within 6 months after surgery, with OS rates of 20% at 6 months and 0% at 20 months ([Figure 1A](#f1-cln_72p294){ref-type="fig"}). OS rates among patients with M0 stage were 61.8% at 1 year, 54.1% at 2 years, 20.3% at 3 years, and 6.8% after 44 months ([Figure 1A](#f1-cln_72p294){ref-type="fig"}). Eleven of 14 patients with calcification died within 13 months after surgery (OS rates of 35.7% at 6 months and 14.3% after 20 months) ([Figure 1B](#f1-cln_72p294){ref-type="fig"}). OS rates in patients without calcification were 67.5% at 1 year, 61.8% at 2 years, 23.2% at 3 years, and 7.7% after 44 months ([Figure 1B](#f1-cln_72p294){ref-type="fig"}).

The OS rate among patients not receiving radiotherapy was 23.5% at 1 year and 8.8% after 27 months *versus* 82.6% at 1 year, 56.5% at 27 months, and 0% at 44 months among patients receiving radiotherapy ([Figure 1C](#f1-cln_72p294){ref-type="fig"}). OS rates among patients not treated with chemotherapy were 42.3% at 1 year, 24.7% at 2 years and 0% at 27 months, compared to 83.6% at 1 year, 74.3% at 2 years, 31.8% at 3 years and 10.6% after 44 months among patients treated with chemotherapy ([Figure 1D](#f1-cln_72p294){ref-type="fig"}). The OS rate among patients receiving both chemotherapy and radiotherapy were 100% at 2 years and 40% at 3 years *versus* 44.4% at 1 year and 29.0% at 2 years among patients without chemotherapy and radiotherapy ([Figure 1E](#f1-cln_72p294){ref-type="fig"}).

Seven of eight patients with postoperative KPS \<80 died within one year after surgery (OS rates were 50% at 6 months and 12.5% after 12 months). In contrast, patients with postoperative KPS scores of ≥80 exhibited OS rates of 68.8% at 1 year, 54.1% at 2 years, 20.3% at 3 years, and 6.8% after 44 months ([Figure 1F](#f1-cln_72p294){ref-type="fig"}). The 1-year, 2-year, 3-year and terminal OS rates were 85.7%, 64.3%, and 32.1% among patients with the WNT subtype, respectively; 84.6%, 72.5%, 18.1% and 0% among patients with the SHH subtype, respectively; and 26.3%, 19.7%, 9.9% and 0% among patients with the non-SHH/WNT subtypes, respectively ([Figure 1G](#f1-cln_72p294){ref-type="fig"}).

Univariate analysis of potential predictors of disease progression
------------------------------------------------------------------

As shown in [Table 3](#t3-cln_72p294){ref-type="table"}, the number of symptoms (e.g., headache, vomiting, ataxia, nystagmus, cranial nerve palsy, increased head circumference, hernia, and secondary epilepsy), M stage, and postoperative radiotherapy were associated with disease progression. Patients with ≥2 symptoms had 2.61-fold higher risk of disease progression (95% CI: 1.10--6.19, *p*=0.029). In addition, patients with M1 stage or above had 20.76 times (95% CI: 3.77--114.29, *p*\<0.001) higher risk of disease progression. Finally, postoperative radiotherapy was protective against disease progression (HR=0.39; 95% CI: 0.16--0.93, *p*=0.033).

Univariate analysis of potential predictors of recurrence
---------------------------------------------------------

The univariate analysis indicated that recurrence was associated with a higher risk of death (HR=2.49, 95% CI: 1.07--40.80, *p*=0.040; [Table 2](#t2-cln_72p294){ref-type="table"}); the 1- and 3-year OS rates of patients without recurrence were 70% and 42%, compared to 43.7% and 0% among patients with recurrence. We next determined which factors were associated with recurrence via a univariate analysis. As shown in [Table 4](#t4-cln_72p294){ref-type="table"}, the risk of recurrence increased with advanced M stage (HR=30.71; 95% CI: 3.92--240.44, *p*=0.001). In contrast, patients receiving both chemotherapy and radiotherapy were less likely to experience recurrence than patients with only one therapy or without either radiotherapy or chemotherapy (HR=0.21, 95% CI: 0.05--0.93, *p*=0.040).

DISCUSSION
==========

In this retrospective analysis, we identified the clinical characteristics, including molecular subtypes, and treatment outcomes associated with the prognosis of pediatric patients with medulloblastoma in China. M stage, calcification, postoperative treatment (radiotherapy, chemotherapy, and both), postoperative KPS score, and molecular subtype were all associated with the OS of medulloblastoma patients. Factors associated with disease progression included number of symptoms, M stage and postoperative radiotherapy. M stage and postoperative radiotherapy or chemotherapy were associated with recurrence. Considered together, molecular subtyping of medulloblastoma was more predictive of survival than histopathology in patients undergoing adjuvant therapy.

This is the first study to report the clinical features, prognoses, and risk factors of patients with pediatric medulloblastoma among a Chinese Han population. As a single-center study in China, this report has inherent, unique ethnic characteristics, which could be regarded as important supplementary information for global studies regarding pediatric medulloblastoma. In addition, this is the first study to compare the prognosis obtained using molecular typing compared to pathological classification in a single-center study. Specifically, this study highlights the advantages of molecular typing, which provides a more intuitive and reliable indicator of molecular classification for prognosis than pathological classification.

In the present study, no differences among patient outcomes were detected between the pathological types. Because the prognosis of patients with the same pathological type of medulloblastoma can be drastically different due to varying genetic backgrounds [@b12-cln_72p294], the development of new molecular subtyping of medulloblastoma is necessary. In the present study, molecular subtyping analyses revealed that almost half of the children presented with the non-SHH/WNT subtype. Furthermore, our univariate and multivariable analyses both indicated that the prognoses of patients with the WNT subtype was the best followed by the SHH subtype of medulloblastoma. These findings are consistent with another study of medulloblastoma in China [@b13-cln_72p294]. Our results further confirmed the prognostic superiority of determining molecular subtypes over pathological types. However, the molecular subtypes (as determined by YAP1 and GAB1) were not associated with disease recurrence or progression. Therefore, further studies are required to identify additional markers, such as glutamate (a predictive marker for patient survival for pediatric medulloblastoma [@b14-cln_72p294]), to improve molecular subtyping of medulloblastoma among children. In addition, consensus regarding the method for identifying medulloblastoma subtypes (e.g., immunohistochemistry, *CTNNB1* mutation analysis, or quantitative PCR) [@b15-cln_72p294] should be reached through additional studies. Finally, larger studies will permit the patients to be further divided into those having Group 3 and Group 4 tumors in order to more completely subtype the tumors and their prognostic impact.

In the present study, disease progression was associated with the presence of \>2 symptoms, which might be related to the special location of medulloblastoma in children. Medulloblastoma is usually present in the midline of the posterior fossa and may cause disordered cerebrospinal fluid circulation resulting in cerebellar dysfunction characterized by intracranial hypertension and cerebellar tissue destruction [@b16-cln_72p294]. The clinical symptoms mainly include headache, vomiting, ataxia, nystagmus, cranial nerve palsy, an increase in head circumference, cerebral hernia and secondary epilepsy. Nervous system injury caused by the cancer or cerebral hernia due to intracranial hypertension can directly threaten the life of the patient. Previous studies have confirmed that the time interval between disease onset and surgery may directly affect the prognosis of a patient with medulloblastoma [@b17-cln_72p294], which may be related to greater symptom severity.

The staging for medulloblastoma is mainly based on the Chang staging system, which is based on the pre-operative imaging and intra-operative findings to determine M stage and T stage. M stage is better for assessing the prognosis of children with medulloblastoma than T stage [@b1-cln_72p294],[@b15-cln_72p294], which is consistent with the present study in which OS as well as disease progression and recurrence were significantly associated with M stage (M0 *vs*. ≥M1). However, no such associations were observed with T stage (T1-2 *vs*. T3-4).

The postoperative KPS score has also been used in the determination of postoperative prognosis. In the present study, postoperative KPS scores ≥80 were associated with significantly longer OS. In addition to the KPS score, OS was also associated with tumor calcification that could be visualized with an imaging examination. Our univariate and multivariable analyses both indicated that patients receiving postoperative radiotherapy or chemotherapy exhibited significantly better OS rates than patients not receiving postoperative radiotherapy or chemotherapy, which is consistent with previous studies [@b12-cln_72p294],[@b13-cln_72p294]. Given the toxicity of radiotherapy and chemotherapy to the nervous system in children [@b18-cln_72p294], in depth studies are necessary to examine individualized therapies according to the risk stratification of medulloblastoma patients. For example, the dose of radiation or chemotherapeutics may be reduced in children with a low risk for recurrence, which may minimize the associated toxicity without compromising the therapeutic effectiveness.

An age of \<3 years has been identified as a factor associated with poor prognosis in medulloblastoma patients [@b19-cln_72p294]. However, no such association was observed in the present study. In addition, previous studies have shown that the extent of resection was a key factor affecting the prognosis of medulloblastoma patients [@b20-cln_72p294],[@b21-cln_72p294]. Pogorzala et al. [@b22-cln_72p294] reported that incomplete surgical resection was associated with poor outcomes. However, OS times were similar in children with total resection and in those with subtotal resection. Furthermore, OS time was comparable between patients with and without tumors that were adherent to the brainstem. Although these differences may be due to the small sample size in the present study, we speculate that total resection should not be performed if it is difficult to completely remove the cancer, especially given the evidence showing that the residual cancer cells will be cleared by postoperative radiotherapy [@b23-cln_72p294].

This study is limited in that the results are from a single institution and the study size was small, which was due in part due to patients not seeking therapy as a result of a poor prognosis or financial burden. In addition, the neurosurgical department at our hospital is relatively new. Thus, the results need to be confirmed with larger sample sizes. In addition, the precise types of chemotherapy and radiotherapy and their influence on patient prognosis were not determined. Moreover, only 35% of the patients were treated with chemotherapy, and 57.5% of the patients were treated with radiotherapy, which was due, in part, to the large proportion of patients under 3 years of age (27.5%). However, this factor may have affected the OS rate, which was only 32.5%. Finally, limitations regarding the immunohistochemistry method utilized for subtype classification did not permit the separation of medulloblastoma groups 3 and 4 molecular, which could be identified via mRNA analysis [@b24-cln_72p294]. Therefore, differences between the subtypes would not have been identified.

Molecular subtypes are better determinants of the prognoses of medulloblastoma patients than pathological types, which may be used to guide the therapy of medulloblastoma. Further studies are necessary to validate our results with a larger sample size and to identify and improve the novel markers of different medulloblastoma subtypes to make this approach more reliable.
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###### 

Characteristics of the medulloblastoma patients (n=40).

  Variables                                Classification                Partial resection (n=6)   Complete resection (n=34)   *p*
  ---------------------------------------- ----------------------------- ------------------------- --------------------------- -----------
  Characteristics                                                                                                              
      Age, y                               \< 3                          1 (16.7)                  10 (29.4)                   0.519
                                           ≥ 3                           5 (83.3)                  24 (70.6)                   
      Sex                                  Female                        3 (50)                    8 (23.5)                    0.181
                                           Male                          3 (50)                    26 (76.5)                   
  Clinical features                                                                                                            
      Tumor site                           Central                       1 (16.7)                  3 (8.8)                     0.555
                                           Peripheral                    5 (83.3)                  31 (91.2)                   
      Number of symptoms                   ≤ 2                           2 (33.3)                  20 (58.8)                   0.247
                                           \> 2                          4 (66.7)                  14 (41.2)                   
      Tumor connecting to brainstem        No                            3 (50)                    17 (50)                     0.999
                                           Yes                           3 (50)                    17 (50)                     
      Ventriculo-peritoneal shunt          No                            3 (50)                    18 (52.9)                   0.894
                                           Yes                           3 (50)                    16 (47.1)                   
      Histological type                    Classic                       5 (83.3)                  28 (82.4)                   0.954
                                           Large cell or desmoplastic    1 (16.7)                  6 (17.6)                    
      M stage                              M0                            5 (83.3)                  30 (88.2)                   0.738
                                           ≥ M1                          1 (16.7)                  4 (11.8)                    
      T stage                              T1-2                          1 (16.7)                  7 (20.6)                    0.825
                                           T3-4                          5 (83.3)                  27 (79.4)                   
      Cystic-solid node                    No                            3 (50)                    20 (58.8)                   0.687
                                           Yes                           3 (50)                    14 (41.2)                   
      Calcification                        No                            3 (50)                    23 (67.6)                   0.403
                                           Yes                           3 (50)                    11 (32.4)                   
      Cerebrospinal fluid fistula          No                            5 (83.3)                  26 (76.5)                   0.711
                                           Yes                           1 (16.7)                  8 (23.5)                    
      Cerebral herniation                  No                            6 (100)                   26 (76.5)                   0.184
                                           Yes                           0 (0)                     8 (23.5)                    
      Postoperative radiotherapy           No                            0 (0)                     17 (50)                     **0.022**
                                           Yes                           6 (100)                   17 (50)                     
      Postoperative chemotherapy           No                            4 (66.7)                  22 (64.7)                   0.926
                                           Yes                           2 (33.3)                  12 (35.3)                   
      Both radiotherapy and chemotherapy   None or singly therapy only   4 (66.7)                  27 (79.4)                   0.491
                                           Both therapies                2 (33.3)                  7 (20.6)                    
      Postoperative KPS score              \< 80                         0 (0)                     8 (23.5)                    0.184
                                           ≥ 80                          6 (100)                   26 (76.5)                   
      Molecular subtype                    WNT                           0 (0)                     8 (23.5)                    0.352
                                           SHH                           3 (50)                    10 (29.4)                   
                                           Non-SHH / WNT                 3 (50)                    16 (47.1)                   
  Long-term outcome                                                                                                            
      Disease progression                  No                            2 (33.3)                  16 (47.1)                   0.533
                                           Yes                           4 (66.7)                  18 (52.9)                   
      Recurrence                           No                            1 (16.7)                  19 (55.9)                   0.077
                                           Yes                           5 (83.3)                  15 (44.1)                   
      Death                                No                            1 (16.7)                  12 (35.3)                   0.369
                                           Yes                           5 (83.3)                  22 (64.7)                   

**Abbreviations:** KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.

###### 

Univariate Cox proportional hazard model of factors associated with poor survival.

  Variables                            HR (95% CI)          *p*-value
  ------------------------------------ -------------------- -----------
  Age, y                                                    
      \< 3                             Reference            
      ≥ 3                              0.67 (0.30, 1.52)    0.342
  Sex                                                       
      Female                           Reference            
      Male                             0.95 (0.41, 2.20)    0.914
  Tumor site                                                
      Peripheral                       Reference            
      Central                          0.78 (0.23, 2.63)    0.684
  Number of symptoms                                        
      ≤ 2                              Reference            
      \> 2                             2.17 (1.00, 4.72)    0.051
  Tumor connecting to brainstem                             
      No                               Reference            
      Yes                              1.11 (0.51, 2.44)    0.791
  Ventriculo-peritoneal shunt                               
      No                               Reference            
      Yes                              0.92 (0.43, 1.98)    0.837
  Tumor resection                                           
      Partial                          Reference            
      Complete                         0.84 (0.31, 2.26)    0.735
  Histological type                                         
      Classic                          Reference            
      Large cell or desmoplastic       1.25 (0.46, 3.39)    0.656
  M stage                                                   
      M0                               Reference            
      ≥ M1                             3.63 (1.30, 10.09)   **0.014**
  T stage                                                   
      T3-4                             Reference            
      T1-2                             0.90 (0.36, 2.26)    0.825
  Cystic-solid node                                         
      No                               Reference            
      Yes                              1.33 (0.62, 2.88)    0.462
  Calcification                                             
      No                               Reference            
      Yes                              3.10 (1.28, 7.53)    **0.012**
  Cerebrospinal fluid fistula                               
      No                               Reference            
      Yes                              2.61 (1.03, 6.65)    **0.044**
  Cerebral herniation                                       
      No                               Reference            
      Yes                              0.67 (0.25, 1.78)    0.423
  Postoperative radiotherapy                                
      No                               Reference            
      Yes                              0.34 (0.16, 0.74)    **0.007**
  Postoperative chemotherapy                                
      No                               Reference            
      Yes                              0.19 (0.06, 0.59)    **0.004**
  Both radiotherapy and chemotherapy                        
      None or singly therapy only      Reference            
      Both therapies                   0.28 (0.10, 0.79)    **0.017**
  Postoperative KPS score                                   
      \< 80                            Reference            
      ≥ 80                             0.31 (0.12, 0.8)     **0.015**
  Molecular subtype                                         
      Non-SHH / WNT                    Reference            
      WNT                              0.16 (0.05, 0.58)    **0.005**
      SHH                              0.29 (0.12, 0.73)    **0.008**
  Recurrence                                                **0.040**
      No                               Reference            
      Yes                              2.49 (1.07, 40.80)   

Bold values indicate statistical significance, *p* \< 0.05.

**Abbreviations:** HR, hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.

###### 

Univariate Cox proportional hazard model of factors associated with disease progression.

  Variables                            HR (95% CI)            *p*-value
  ------------------------------------ ---------------------- -------------
  Age, y                                                      
      \< 3                             Reference              
      ≥ 3                              0.63 (0.26, 1.51)      0.299
  Sex                                                         
      Female                           Reference              
      Male                             0.74 (0.29, 1.90)      0.528
  Tumor site                                                  
      Peripheral                       Reference              
      Central                          0.68 (0.20, 2.32)      0.542
  Number of symptoms                                          
      ≤ 2                              Reference              
      \> 2                             2.61 (1.10, 6.19)      **0.029**
  Tumor connecting to brainstem                               
      No                               Reference              
      Yes                              1.88 (0.79, 4.48)      0.157
  Ventriculo-peritoneal shunt                                 
      No                               Reference              
      Yes                              1.58 (0.66, 3.77)      0.308
  Level of tumor section                                      
      Subtotal                         Reference              
      Total                            0.84 (0.28, 2.51)      0.749
  Histological type                                           
      Classic                          Reference              
      Large cell or desmoplastic       1.15 (0.39, 3.40)      0.805
  M stage                                                     
      M0                               Reference              
      ≥ M1                             20.76 (3.77, 114.29)   **\<0.001**
  T stage                                                     
      T3-4                             Reference              
      T1-2                             2.21 (0.85, 5.73)      0.104
  Cystic-solid node                                           
      No                               Reference              
      Yes                              1.50 (0.65, 3.47)      0.347
  Calcification                                               
      No                               Reference              
      Yes                              2.23 (0.93, 5.36)      0.074
  Cerebrospinal fluid fistula                                 
      No                               Reference              
      Yes                              2.45 (0.98, 6.12)      0.055
  Cerebral herniation                                         
      No                               Reference              
      Yes                              0.62 (0.21, 1.84)      0.392
  Postoperative radiotherapy                                  
      No                               Reference              
      Yes                              0.39 (0.16, 0.93)      **0.033**
  Postoperative chemotherapy                                  
      No                               Reference              
      Yes                              0.45 (0.18, 1.15)      0.094
  Both radiotherapy and chemotherapy                          
      No                               Reference              
      Yes                              3.38 (0.98, 11.65)     0.054
  Postoperative KPS score                                     
      \< 80                            Reference              
      ≥ 80                             0.45 (0.17, 1.18)      0.104
  Molecular subtype                                           
      Non-SHH / WNT                    Reference              
      WNT                              0.46 (0.15, 1.44)      0.183
      SHH                              0.40 (0.15, 1.09)      0.074

Bold values indicate statistical significance, *p* \< 0.05.

**Abbreviations:** HR, hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.

###### 

Univariate Cox proportional hazard model of factors associated with medulloblastoma recurrence.

  Variables                            HR (95% CI)            *p*-value
  ------------------------------------ ---------------------- -----------
  Age, y                                                      
      \< 3                             Reference              
      ≥ 3                              0.54 (0.22, 1.32)      0.178
  Gender                                                      
      Female                           Reference              
      Male                             0.51 (0.2, 1.29)       0.155
  Tumor site                                                  
      Peripheral                       Reference              
      Central                          0.97 (0.22, 4.22)      0.970
  Number of symptoms                                          
      ≤ 2                              Reference              
      \> 2                             2.27 (0.93, 5.55)      0.073
  Tumor connecting to brainstem                               
      No                               Reference              
      Yes                              2.05 (0.81, 5.14)      0.128
  Ventriculo-peritoneal shunt                                 
      No                               Reference              
      Yes                              1.6 (0.64, 4.01)       0.317
  Level of tumor section                                      
      Subtotal                         Reference              
      Total                            0.54 (0.19, 1.52)      0.243
  Histological type                                           
      Classic                          Reference              
      Large cell or desmoplastic       1.26 (0.42, 3.78)      0.679
  M stage                                                     
      M0                               Reference              
      ≥ M1                             30.71 (3.92, 240.44)   **0.001**
  T stage                                                     
      T3-4                             Reference              
      T1-2                             1.48 (0.49, 4.48)      0.492
  Cystic-solid node                                           
      No                               Reference              
      Yes                              1.22 (0.5, 2.95)       0.666
  Calcification                                               
      No                               Reference              
      Yes                              2.17 (0.86, 5.48)      0.100
  Cerebrospinal fluid fistula                                 
      No                               Reference              
      Yes                              2.28 (0.86, 6.04)      0.098
  Cerebral herniation                                         
      No                               Reference              
      Yes                              0.68 (0.23, 2.04)      0.489
  Postoperative radiotherapy                                  
      No                               Reference              
      Yes                              0.60 (0.24, 1.47)      0.261
  Postoperative chemotherapy                                  
      No                               Reference              
      Yes                              0.41 (0.16, 1.11)      0.079
  Both radiotherapy and chemotherapy                          
      No                               Reference              
      Yes                              0.21 (0.05, 0.93)      **0.040**
  Postoperative KPS score                                     
      \< 80                            Reference              
      ≥ 80                             0.68 (0.22, 2.06)      0.492
  Molecular subtype                                           
      Non-SHH / WNT                    Reference              
      WNT                              0.61 (0.18, 2.01)      0.417
      SHH                              0.64 (0.23, 1.74)      0.379

Bold values indicate statistical significance, *p* \<0.05.

**Abbreviations:** HR, hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Scale; SHH, sonic hedge hog.
